^
Association details:
| Biomarker: | U2AF1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | HPB-092 (FLT3 inhibitor, IRAK-4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4492 / 17 - A novel and potent FLT3 and IRAK4 dual inhibitor for the treatment of acute myeloid leukemia
Published date:
03/15/2023
Excerpt:
HPB-092 significantly inhibited MV4-11 tumor cell proliferation at low nanomole concentration….These results underscore the potential therapeutic benefit and safety profile of HPB-092 for the treatment of AML, especially in patients with mutations in U2AF1 or SF3B1 spliceosome.
